Drug treatment of hyperlipidemia.
The most frequent indication for treatment of hyperlipidemia is for prevention of arteriosclerosis, a suspected but unproved benefit. The cornerstone of treatment of primary hyperlipidemia is diet; drugs may be added to, but do not replace, diet. When a drug is used with any patient, its potential benefits and hazards must be carefully weighed for the given subject. The subjects should be carefully followed and observed for side effects. Plasma lipids should be monitored during the course of treatment. Five drugs have been approved by the U.S. Food and Drug Administration for the treatment of hyperlipidemia: cholestyramine, clofibrate, nicotinic acid, sodium dextrothyroxine and beta-sitosterol. The use, the actions and the side effects of each and of several nonapproved agents are discussed.
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D045930:Anabolic Agents / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D003084:Colestipol / Q000627:therapeutic use; D003918:Dextrothyroxine / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D006218:Halofenate / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000188:drug therapy*; D009355:Neomycin / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use; D011374:Progesterone / Q000627:therapeutic use; D012855:Sitosterols / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D045930:Anabolic Agents; D004967:Estrogens; D009539:Nicotinic Acids; D012855:Sitosterols; D002792:Cholestyramine Resin; D011374:Progesterone; D003918:Dextrothyroxine; D002994:Clofibrate; D009355:Neomycin; D003084:Colestipol; D006218:Halofenate